Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06055959 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
A Phase 2 study of Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 9
- Study locations
NCT06055959 is a Phase 2 study of Generalized Myasthenia Gravis that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 8 participants, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (94% lower). The trial reports 9 study locations across 3 states.
The verdict
NCT06055959, a Phase 2 study of Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
Conditions Studied
Interventions
- DRUG Zilucoplan
Study Locations (9)
Other
- Mg0014 40144 - Milan
- Mg0014 40774 - Katowice
- Mg0014 40218 - Warsaw
- Mg0014 20104 - Seoul
- Mg0014 20220 - Seoul
- Mg0014 40735 - Glasgow
- Mg0014 40736 - London
Illinois
- Mg0014 50168 - Chicago
Texas
- Mg0014 50574 - Denton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2026-12-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06055959
The ClinicalTrials.gov registry entry for NCT06055959 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (94% lower). The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which Zilucoplan is the first listed.
NCT06055959 reports 9 study locations spanning 3 distinct geographic areas - top geographies include Other, Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT06055959 about?
NCT06055959 is a clinical study titled "A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis". The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
What is the current status of trial NCT06055959?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2024-10-16. Estimated completion is 2026-12-25.
What conditions does trial NCT06055959 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis.
What interventions are being tested in trial NCT06055959?
The interventions under investigation include: Zilucoplan (DRUG).
Who is sponsoring clinical trial NCT06055959?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06055959 being conducted?
This trial has 9 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
RECRUITING · Phase 2
-
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.